Immunicum AB Publishes Prospectus in Connection with Rights Issue and Listing on Nasdaq Stockholm

Press Release

5 December 2017

Immunicum AB Publishes Prospectus in Connection with Rights Issue and Listing on Nasdaq Stockholm

Immunicum AB (publ) ("Immunicum" or "the Company"), First North Premier: (IMMU), a biopharmaceutical company advancing an off-the-shelf immune system primer against a range of solid tumors, held on 4 December 2017 an Extraordinary General Meeting, which resolved to approve the board of directors' resolution on a new issue of shares with preferential rights for the shareholders.

The prospectus that has been prepared in connection with the rights issue and the listing on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority and is now available on Immunicum's website, www.immunicum.com and Pareto Securities AB's website, www.paretosec.com/corp/immunicum.

Summary of the rights issue

  • Shareholders who are registered in the Company's share ledger kept by Euroclear Sweden AB on the record date 6 December 2017 will receive one subscription right for each share held in Immunicum.
  • The last day of trading in the shares including a right to participate in the rights issue was 4 December 2017.
  • The subscription rights entitle the holder to subscribe for new shares with preferential rights, whereupon 14 subscription rights entitle the holder to subscribe for 15 new shares.
  • The subscription price is SEK 8 per share.
  • At full subscription, Immunicum will receive issue proceeds of approximately SEK 223 million before issue costs.
  • The subscription period runs during the period 8 December 2017 to 22 December 2017.
  • Trading in subscription rights occurs during the period 8 December 2017 to 20 December 2017.

On 24 November 2017, Nasdaq Stockholm AB's listing committee decided to approve the Company's application for admission to trading on Nasdaq Stockholm, conditional upon the Company completing the rights issue and securing sufficient working capital for the twelve month period following the admission to trading, and also conditional upon completion of customary listing conditions.

Preliminarily schedule for listing on Nasdaq Stockholm

  • Last day of trading on Nasdaq First North Premier: 12 January 2018
  • First day of trading on Nasdaq Stockholm: 15 January 2018

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com

Investor and Media Relations EU/US

Gretchen Schweitzer
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com